Stimulus intensity in left ventricular leads and response to cardiac resynchronization therapy

Venkata V Bavikati, Jonathan J Langberg, B Robinson Williams 3rd, Danesh Kella, Michael S Lloyd, Venkata V Bavikati, Jonathan J Langberg, B Robinson Williams 3rd, Danesh Kella, Michael S Lloyd

Abstract

Background: Increased left ventricular (LV) stimulus intensity has been shown to improve conduction velocity and cardiac output. However, high-output pacing would shorten device battery life. Our prospective trial analyzed the clinical effects of high- versus low-output LV pacing.

Methods and results: Thirty-nine patients undergoing initial cardiac resynchronization therapy device implantation with bipolar LV leads were assigned to 3 months of either high-output LV pacing (Hi) or low-output LV pacing (Lo) in a randomized, blinded crossover fashion. Hi and Lo settings were determined with a rigorous intraoperative protocol specific to each patient. Clinical and echocardiographic data were obtained at randomization, at 3 months, and a subsequent 3 months after crossover. Mean age was 66.4±9.8 years, and mean QRS duration was 159.3±23.1 ms. Compared to baseline, both arms had significant improvements in Minnesota Living With Heart Failure score (given as mean [95% confidence interval]) (baseline versus Lo: 43.3 [35.5 to 51.1] versus 21.3 [14.6 to 28.0], P<0.01; baseline versus Hi: 43.3 [35.5 to 51.1] versus 23.6 [16.1 to 31.1], P<0.01) and 6-minute walk distance (baseline versus Lo: 692 ft [581 to 804] versus 995 ft [876 to 1114], P<0.01; baseline versus Hi: 699 ft [585 to 813] versus 982 ft [857 to 1106], P<0.01). Although both Hi and Lo arms had some echocardiographic parameters that significantly improved compared to baseline (baseline end-diastolic diameter 5.7 cm [5.5 to 6.0] versus Lo 5.5 cm [5.1 to 5.8], P<0.01; baseline end-systolic diameter 4.9 cm [4.6 to 5.3] versus Hi 4.7 cm [4.3 to 5.0], P<0.05), there were no significant differences observed when comparing the Hi- versus Lo-output arms.

Conclusions: Low-output LV pacing with a relatively narrow safety margin above capture threshold affords significant improvement from baseline and is clinically equivalent to high-output LV pacing. These data support a strategy of minimizing the programmed LV safety margin to increase battery life in cardiac resynchronization therapy devices.

Clinical trial registration information: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01060449.

Keywords: cardiac resynchronization; congestive heart failure; pacing.

Figures

Figure 1.
Figure 1.
Protocol design of the SILVeR-CRT trial. FU indicates follow-up.
Figure 2.
Figure 2.
Differences on ECG between Lo and Hi LV-only bipolar pacing for 2 study participants. The QRS morphology differences are most notable in the frontal leads for the patient on left and in leads III, aVL, and aVF for the patient on right. (Lead I is not shown to protect subject identifiers).

References

    1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
    1. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J. 2011;75:521-527.
    1. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J, III, St John Sutton M, De Sutter J, Murillo J. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-2616.
    1. Leon AR, Abraham WT, Curtis AB, Daubert JP, Fisher WG, Gurley J, Hayes DL, Lieberman R, Petersen-Stejskal S, Wheelan K. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol. 2005;46:2348-2356.
    1. Delgado V, van Bommel RJ, Bertini M, Borleffs CJ, Marsan NA, Ng AT, Nucifora G, van de Veire NR, Ypenburg C, Boersma E, Holman ER, Schalij MJ, Bax JJ. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation. 2011;123:70-78.
    1. Gorcsan J. Finding pieces of the puzzle of nonresponse to cardiac resynchronization therapy. Circulation. 2011;123:10-12.
    1. Auricchio A, Fantoni C, Regoli F, Carbucicchio C, Goette A, Geller C, Kloss M, Klein H. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation. 2004;109:1133-1139.
    1. Sweeney MO, Prinzen FW. Ventricular pump function and pacing. Circulation. 2008;1:127-139.
    1. Becker M, Franke A, Breithardt OA, Ocklenburg C, Kaminski T, Kramann R, Knackstedt C, Stellbrink C, Hanrath P, Schauerte P, Hoffmann R. Impact of left ventricular lead position on the efficacy of cardiac resynchronisation therapy: a two-dimensional strain echocardiography study. Heart. 2007;93:1197-1203.
    1. Burri H, Gerritse B, Davenport L, Demas M, Sticherling C. Fluctuation of left ventricular thresholds and required safety margin for left ventricular pacing with cardiac resynchronization therapy. Europace. 2009;11:931-936.
    1. Thakor NV, Ranjan R, Rajasekhar S, Mower MM. Effect of varying pacing waveform shapes on propagation and hemodynamics in the rabbit heart. Am J Cardiol. 1997;79:36-43.
    1. Roth BJ, Wikswo JP., Jr Electrical stimulation of cardiac tissue: a bidomain model with active membrane properties. IEEE Trans Biomed Eng. 1994;41:232-240.
    1. Wikswo JP, Jr, Wisialowski TA, Altemeier WA, Balser JR, Kopelman HA, Roden DM. Virtual cathode effects during stimulation of cardiac muscle: two-dimensional in vivo experiments. Circ Res. 1991;68:513-530.
    1. Theis C, Bavikati VV, Langberg JJ, Lloyd MS. The relationship of bipolar left ventricular pacing stimulus intensity to cardiac depolarization and repolarization in humans with cardiac resynchronization devices. J Cardiovasc Electrophysiol. 2009;20:645-649.
    1. Sauer WH, Sussman JS, Verdino RJ, Cooper JM. Increasing left ventricular pacing output decreases interventricular conduction time in patients with biventricular pacing systems. Pacing Clin Electrophysiol. 2006;29:569-573.
    1. Tedrow UB, Stevenson WG, Wood MA, Shepard RK, Hall K, Pellegrini CP, Ellenbogen KA. Activation sequence modification during cardiac resynchronization by manipulation of left ventricular epicardial pacing stimulus strength. Pacing Clin Electrophysiol. 2007;30:65-69.
    1. Schaer BA, Koller MT, Sticherling C, Altmann D, Joerg L, Osswald S. Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity. Heart Rhythm. 2009;6:1737-1743.
    1. Poole JE, Gleva MJ, Mela T, Chung, Mina K, Uslan DZ, Borge R, Gottipaty V, Shinn T, Dan D, Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell K, Holcomb Rfor the REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures. Circulation. 2010;122:1553-1561.
    1. Bhan A, Kapetanakis S, Monaghan MJ. Optimization of cardiac resynchronization therapy. Echocardiography. 2008;25:1031-1039.
    1. Buck S, Maass AH, Nieuwland W, Anthonio RL, Van Veldhuisen DJ, Van Gelder IC. Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy. Europace. 2008;10:1313-1319.
    1. Wikswo JP, Jr, Lin SF, Abbas RA. Virtual electrodes in cardiac tissue: a common mechanism for anodal and cathodal stimulation. Biophys J. 1995;69:2195-2210.
    1. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-1338.

Source: PubMed

3
Prenumerera